Carotuximab
Modify Date: 2024-01-14 00:56:14
Carotuximab structure
|
Common Name | Carotuximab | ||
|---|---|---|---|---|
| CAS Number | 1268714-50-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CarotuximabCarotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2]. |
| Name | Carotuximab |
|---|
| Description | Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Carotuximab (TRC105；300 μg/mL；预处理 1 小时，然后共培养 12 小时) 降低人主动脉内皮细胞中 7-酮胆固醇诱导的内皮糖蛋白 (Eng) 蛋白水平和 pSmad1/5 和 pSmad2/3 信号通路。Carotuximab 介导的 Eng 阻断阻止了 7-酮胆固醇诱导的单核细胞通过内皮单层细胞的粘附和迁移[1]。 Western Blot Analysis[1] Cell Line: Human aortic endothelial cells (HAoECs) Concentration: 300 μg/mL Incubation Time: Pretreatment 1 h, and then co-cultured for 12 h Result: Reduced the 7-Ketocholesterol-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling. |
| In Vivo | Carotuximab（TRC105；2 mg/kg；i.v；每 3 天一次；持续 8 周）与 Decitabine 一起在急性髓性白血病 (AML) 异种移植物中产生更持久的抗白血病作用，并且还能增强活性氧 (ROS) 活性[2]。 Animal Model: Female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; 7-8 weeks) injected with primary AML-0032 cells[2] Dosage: 2 mg/kg Administration: i.v; every 3 days; for 8 weeks Result: Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts. |
| References |
| No Any Chemical & Physical Properties |